Menu

Broadly Neutralizing Antibodies in HIV Patients

Researchers identify aspects of the patient, the virus, and the infection itself that influence whether a person with HIV will produce broadly neutralizing antibodies.

Sep 28, 2016
Jef Akst

WIKIMEDIA, BRUCEBLAUSEOnly about 1 percent of HIV-infected people will generate the broadly neutralizing antibodies that target conserved spiked viral structures and can thus recognize multiple strains, and could one day serve as the basis for an effective vaccine. Now, thanks to work out of the University of Zurich and University Hospital Zurich (UZH) in Switzerland, researchers have a few clues as to who makes these broadly neutralizing antibodies and when. The team’s results were published this week (September 26) in Nature Medicine.

“Our results show how different factors boost the formation of antibodies that broadly combat different viral strains. This will pave the way for us to systematically push ahead with the development of an effective vaccine against HIV,” study coauthor Alexandra Trkola, a professor of medical virology at UZH, said in a press release.

Examining some 4,500 HIV+ participants of the Swiss HIV Cohort Study and the Zurich Primary HIV Infection Study, the researchers found that 239 of them had formed broadly neutralizing antibodies. Further analysis revealed that the viral load in the body, the diversity of viruses found in that individual, and how long the patient went without treatment were key factors in determining which patients produced these antibodies.

Interestingly, these factors independently affect broadly neutralizing antibody production, study coauthor Huldrych Günthard, a professor of clinical infectious diseases at UZH, told Medical News Today. “So we don’t necessarily have to consider all three parameters in designing an HIV vaccine. This is especially important with regard to the length of vaccine administration—it wouldn’t be possible to imitate a longer untreated HIV infection with a vaccine.”

Günthard and colleagues also found host-specific factors—including ethnicity—that influenced the probability that a patient would produce broadly neutralizing antibodies: black patients with HIV produce the antibodies more frequently, even when controlling for other factors. Genetics, geographic location, and socioeconomics could all play a role, the authors noted.

Thirdly, different virus subtypes appeared more or less likely to trigger the production of broadly neutralizing antibodies. Subtype B viruses, the researchers found, tend to elicit antibodies that bind to CD4 binding sites on the virus, while other subtypes tend to elicit antibodies that bind to V2 glycan, a sugar element of HIV’s conserved spikes.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.